ArticleFrontiers in cardiovascular medicine2025
The impact of inflammatory burden index on the prognosis in acute decompensated heart failure: evidence from a cohort study in Jiangxi, China.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute decompensated heart failure (ADHF) is the most common and severe type of HF. The aim of this study is to evaluate the impact and predictive value of a novel inflammatory marker, the inflammatory burden index (IBI), on the 30-day mortality and adverse prognosis in patients with ADHF. Methods: This retrospective cohort study included 1,241 ADHF patients from Jiangxi Provincial People's Hospital between 2018 and 2024. The IBI was calculated as C-reactive protein × (neutrophil count/lymphocyte count). In the event analysis, the study outcome was defined as the 30-day mortality rate after hospital admission in ADHF patients. Multivariable Cox regression and receiver operating characteristic curve analysis were used to assess the impact and predictive value of the IBI on 30-day mortality. Additionally, subgroup analyses were performed to determine the risk dependency of the IBI within specific populations. Results: During the 30-day observation period, a total of 108 death events (8.70%) were recorded. When the study population was stratified into tertiles based on the IBI, the 30-day mortality rates were 1.93%, 4.60%, and 19.57%, respectively. Multivariable Cox regression analysis revealed a significant positive association between the IBI and 30-day mortality in ADHF patients (HR per SD increase: 1.29, 95% CI: 1.15-1.46). Compared to ADHF patients with a low IBI (T1), those with a high IBI (T3) showed a 368% higher risk of 30-day mortality (HR: 4.68, 95% CI: 1.06-13.73). Subgroup analysis revealed a significant interaction between the IBI and 30-day mortality in ADHF patients across sex subgroups ( Conclusion: The cohort study conducted in Jiangxi, China, revealed that the novel inflammatory marker IBI is significantly positively associated with 30-day mortality in ADHF patients and demonstrated strong predictive value. Incorporating IBI into the clinical management of ADHF patients may hold significant potential for preventing further disease deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.